[go: up one dir, main page]

MA31135B1 - Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. - Google Patents

Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Info

Publication number
MA31135B1
MA31135B1 MA31763A MA31763A MA31135B1 MA 31135 B1 MA31135 B1 MA 31135B1 MA 31763 A MA31763 A MA 31763A MA 31763 A MA31763 A MA 31763A MA 31135 B1 MA31135 B1 MA 31135B1
Authority
MA
Morocco
Prior art keywords
wnt
diagnosis
treatment
mediated disorders
antagonists
Prior art date
Application number
MA31763A
Other languages
Arabic (ar)
English (en)
Inventor
James A Ernst
Paul Polakis
Bonnee Rubinfeld
Almeida Venita I De
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31135B1 publication Critical patent/MA31135B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

La présente invention concerne des antagonistes de wnt chimères comprenant un composant de domaine frz dérivé d'une protéine frizzled, une protéine connexe frizzled secrétée ou une protéine ror et un composant d'immunoglobuline fc, et leur utilisation dans le traitement et la détection aux fins de diagnostic d'une signalisation wnt cellulaire et de troubles à médiation wnt, dont le cancer
MA31763A 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt. MA31135B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82506306P 2006-09-08 2006-09-08
US95117507P 2007-07-20 2007-07-20
PCT/US2007/077845 WO2008031009A2 (fr) 2006-09-08 2007-09-07 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles à médiation wnt

Publications (1)

Publication Number Publication Date
MA31135B1 true MA31135B1 (fr) 2010-02-01

Family

ID=39092004

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31763A MA31135B1 (fr) 2006-09-08 2009-04-06 Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.

Country Status (19)

Country Link
US (5) US7947277B2 (fr)
EP (1) EP2061495A2 (fr)
JP (1) JP2010504081A (fr)
KR (1) KR20090060334A (fr)
AR (1) AR062709A1 (fr)
AU (1) AU2007292242A1 (fr)
BR (1) BRPI0714751A2 (fr)
CA (1) CA2662041A1 (fr)
CL (1) CL2007002609A1 (fr)
CR (1) CR10699A (fr)
IL (1) IL197240A0 (fr)
MA (1) MA31135B1 (fr)
MX (1) MX2009002522A (fr)
NO (1) NO20091413L (fr)
PE (3) PE20081217A1 (fr)
RU (1) RU2009113023A (fr)
SG (2) SG174101A1 (fr)
TW (1) TW200819463A (fr)
WO (1) WO2008031009A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133250A2 (fr) * 2005-10-31 2007-11-22 Austin Gurney Compositions et procédés de diagnostic et de traitement du cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009065938A (ja) * 2007-09-14 2009-04-02 Matsumoto Shika Univ タンパク質、破骨細胞分化阻害剤、炎症性骨破壊治療薬、遺伝子、組み替えベクター、及びタンパク質の製造方法
AU2008334608A1 (en) * 2007-12-13 2009-06-18 Merck Serono S.A. SARP-1 fusion proteins and uses thereof
WO2009132815A1 (fr) 2008-04-30 2009-11-05 Roche Diagnostics Gmbh Utilisation de sfrp-3 dans l’évaluation d’une insuffisance cardiaque
ES2334092B1 (es) * 2008-07-02 2011-01-24 Proyecto De Biomedicina Cima, S.L. Agentes antiangiogenicos.
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010038756A1 (fr) 2008-09-30 2010-04-08 協和発酵キリン株式会社 COMPOSITION PHARMACEUTIQUE DESTINÉE À TRAITER DES MALADIES DES OS COMPRENANT UNE PROTÉINE COMPRENANT UN DOMAINE EXTRACELLULAIRE RICHE EN CYSTÉINE DE TYPE Frizzled1, Frizzled2 ET Frizzled7
WO2010124188A1 (fr) 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps anti-ror1 humain
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (fr) * 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux recepteurs frizzled et leurs utilisations
WO2012006027A1 (fr) * 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Domaines extracellulaires fzd8 et molécules de fusion au domaine extracellulaire fzd8 et traitements les utilisant
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
RU2013122801A (ru) 2010-10-20 2014-11-27 Дженентек, Инк. Способы и композиции для модулирования пути wnt
BR112013012228B1 (pt) * 2010-11-16 2023-02-28 University Of Southern California Método cosmético para tratar uma condição da pele e usos de um composto antagonista de cbp/catenina de molécula pequena
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
JP6121902B2 (ja) 2011-06-21 2017-04-26 協和発酵キリン株式会社 Ｆｒｉｚｚｌｅｄ２の細胞外領域蛋白質のトランケート体を含む蛋白質、および該蛋白質を含有する骨疾患治療用医薬組成物
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
US20130216546A1 (en) * 2012-01-10 2013-08-22 Ngm Biopharmaceuticals, Inc. Methods of Treating Glucose Metabolism Disorders
SG11201404703WA (en) 2012-02-11 2014-09-26 Genentech Inc R-spondin translocations and methods using the same
HRP20190522T1 (hr) 2012-02-20 2019-05-03 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi koji se vežu za humani komplement c5
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
EP2935335B1 (fr) * 2012-12-19 2020-10-28 Affibody AB Nouveaux polypeptides
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP3077546A4 (fr) 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt
EP3166627A1 (fr) 2014-07-11 2017-05-17 Genentech, Inc. Inhibition de la voie de signalisation notch
KR101572606B1 (ko) 2014-11-24 2015-11-27 강원대학교산학협력단 Sfrp5 유래의 펩타이드 및 이를 포함하는 피부 미백용 화장료 조성물
WO2016126054A1 (fr) 2015-02-04 2016-08-11 (주)메드팩토 Composition pour prévenir ou traiter un trouble de l'érection comprenant une protéine dkk2 modifiée ou un gène pour celle-ci, et son procédé d'utilisation
CA3014498A1 (fr) * 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions et methodes pour inhiber la signalisation de wnt
CN108310366A (zh) * 2017-01-15 2018-07-24 复旦大学附属华山医院 重组sfrp5蛋白在制备治疗非酒精性脂肪性肝炎药物中的用途
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
US20230192846A1 (en) * 2019-11-18 2023-06-22 The Regents Of The University Of California Anti-ror-2 antibodies and methods of use
US20230121867A1 (en) * 2019-11-26 2023-04-20 Cedars-Sinai Medical Center Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
WO2025058052A1 (fr) * 2023-09-14 2025-03-20 国立大学法人神戸大学 Procédé de criblage de matériau pour inhiber l'exacerbation de cellules de glioblastome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (fr) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS A BASE DU RECEPTEUR DE Wnt ET PROCEDES D'UTILISATION DE CELLES-CI
DE69735375T3 (de) * 1996-09-24 2010-09-02 Tanox, Inc., Houston Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001058957A2 (fr) * 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps
JP2004516812A (ja) 2000-06-21 2004-06-10 インサイト・ゲノミックス・インコーポレイテッド 受容体
US7413873B2 (en) * 2001-01-30 2008-08-19 The Regents Of The University Of California Method of detection and treatment of colon cancer
US7713526B2 (en) 2001-05-01 2010-05-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
AU2002308557A1 (en) * 2001-05-01 2002-11-11 The Regents Of The University Of California Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
US20030044409A1 (en) 2001-05-01 2003-03-06 Carson Dennis A. Immunologic compositions and methods for studying and treating cancers expressing frizzled antigens
WO2003004045A2 (fr) 2001-07-05 2003-01-16 Xenon Genetics, Inc. Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
EP1549144A4 (fr) * 2002-10-04 2010-01-06 Univ California Methodes de traitement du cancer par inhibition de la signalisation de wnt
WO2004053069A2 (fr) * 2002-12-06 2004-06-24 The Board Of Trustees Of The Leland Stanford Junior University Protection de cellules souches contre des agents cytotoxiques par modulation des voies de signalisation de la $g(b)-catenine
US7803783B2 (en) * 2002-12-06 2010-09-28 The Board Of Trustees Of The Leland Stanford Junior University Use of WNT inhibitors to augment therapeutic index of chemotherapy
US20050096263A1 (en) * 2003-10-30 2005-05-05 Keay Susan K. Novel antiproliferative factor and methods of use
JP5025475B2 (ja) 2004-09-21 2012-09-12 ロード アイランド ホスピタル エー ライフスパン−パートナー Ｗｎｔタンパク質ならびに癌の検出および治療の方法
WO2006036175A2 (fr) 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Proteines wnt et detection et traitement du cancer
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
WO2006055635A2 (fr) 2004-11-15 2006-05-26 Mount Sinai School Of Medicine Of New York University Compositions et methodes de modification de la signalisation autocrine wnt
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth

Also Published As

Publication number Publication date
BRPI0714751A2 (pt) 2014-06-24
US20100266593A1 (en) 2010-10-21
MX2009002522A (es) 2009-06-19
CL2007002609A1 (es) 2008-04-18
SG174101A1 (en) 2011-09-29
IL197240A0 (en) 2011-08-01
PE20120806A1 (es) 2012-07-25
CA2662041A1 (fr) 2008-03-13
WO2008031009A3 (fr) 2009-07-02
PE20081217A1 (es) 2008-09-24
TW200819463A (en) 2008-05-01
SG174100A1 (en) 2011-09-29
KR20090060334A (ko) 2009-06-11
JP2010504081A (ja) 2010-02-12
CR10699A (es) 2009-07-10
US20170349639A1 (en) 2017-12-07
AU2007292242A1 (en) 2008-03-13
EP2061495A2 (fr) 2009-05-27
WO2008031009A2 (fr) 2008-03-13
NO20091413L (no) 2009-06-08
RU2009113023A (ru) 2010-10-20
US20120141481A1 (en) 2012-06-07
PE20120807A1 (es) 2012-07-26
US7947277B2 (en) 2011-05-24
AR062709A1 (es) 2008-11-26
US20110311534A1 (en) 2011-12-22
US20080299136A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
MA31135B1 (fr) Antagonistes de wnt et leur utilisation pour le diagnostic et le traitement de troubles a mediation wnt.
MA30900B1 (fr) Anticorps d'agonistes anti-notch3 et leur utilisation dans le traitement de maladies liées à notch3
EP1578923A4 (fr) Polypeptides mic solubles utilises en tant que marqueurs pour le diagnostic, le pronostic et le traitement d'un cancer et de maladies ou d'affections auto-immunes
EP1810026A4 (fr) B7-h1 et procedes de diagnostic, de pronostic et de traitement du cancer
FR21C1004I2 (fr) Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe
MA44936A1 (fr) Méthodes de diagnostic et de traitement du cancer
WO2008134569A3 (fr) Diagnostic et traitement de la rectocolite hémorragique chez la population portoricaine
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
EP1692318A4 (fr) Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA31156B1 (fr) Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
MA30462B1 (fr) Composes de pyridylamide antagonistes des canaux calciques de type t
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA45801B1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
MA30632B1 (fr) Anticorps humanisé
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
EP2057466A4 (fr) Méthodes et compositions pour le traitement et le diagnostic de l'encéphalite auto-immune ou de l'épilepsie
EP1678195A4 (fr) Techniques et compositions pour le diagnostic et le traitement de la leucemie lymphocytaire chronique des cellules beta
DE602004024549D1 (de) Diagnose und überwachung von hepatozellulärem karzinom
EP1742654A4 (fr) Anticorps anti-lfl2 pour le diagnostic, le pronostic et le traitement d'un cancer
Collins et al. Direct immunofluoresence in vasculitic neuropathy: specificity of vascular immune deposits
WO2003104761A3 (fr) Mesure de peptides de melanocortine et utilisations correspondantes
WO2006099543A3 (fr) Methodes d'evaluation de la toxicite induite par des anticorps
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin